Legendary Peptides files motion to dismiss in Lilly / Retatrutide case
Argument: Lilly doesn’t sell Reta *yet*. Therefore, no harm and no lost Reta sales possible, and theories that buyers switched off Zepbound/Mounjaro/Foundayo, or that gray-market Reta will poison a future launch, are too speculative for standing.
Honestly pretty good argument (for now).